A Machine Learning Model Including Questionnaire and Structural Imaging Data Predicts Headache Improvement in Patients with Acute Post-traumatic Headache Attributed to Mild Traumatic Brain Injury (P8-12.002)
Catherine Chong,Jing Li,Todd Schwedt,Visar Berisha,Devin Nikjou,Teresa Wu,Gina Dumkrieger,Katherine Ross,Lingchao Mao
DOI: https://doi.org/10.1212/wnl.0000000000202432
IF: 9.9
2023-01-01
Neurology
Abstract:Objective: To assess the accuracy of a model including clinical questionnaire and brain structural measures for predicting headache improvement in patients with acute post-traumatic headache (aPTH) attributed to mild traumatic brain injury (mTBI). Background: Our prior work demonstrated that questionnaires assessing psychosocial symptoms have utility of predicting PTH persistence. Here, we aimed to determine whether classification accuracy was improved when adding structural brain measures to the model. Design/Methods: Adults with aPTH (enrolled 0–59 days post-mTBI) underwent T1-weighted brain MRI and completed three selected questionnaires (Sports Concussion Assessment Tool-symptom checklist, Pain Catastrophizing Scale, and the Trait Anxiety Inventory Scale). Total and sub-scores of questionnaires and automated segmentations of regional brain volume, thickness, curvature, and area measures were used to train a dimension reduction model followed by prediction models of headache improvement. In addition, aPTH vs healthy control (HC) brain imaging data were compared. Results: 43 patients with aPTH (mean age=43.0, SD=12.4) and 61 HC were enrolled (mean age= 39.1, SD=12.8). At three-month follow-up, 26 aPTH patients had headache improvement and 17 did not. The final model trained on questionnaire data and brain measurements achieved cross-validation Area Under the Curve classification accuracy of 0.801 for predicting headache improvement. The most highly contributing model features included questionnaires assessing psychosocial symptoms and brain structural measurements including curvature and thickness in of superior, middle, and inferior temporal, fusiform, inferior parietal, and lateral occipital regions. At baseline, those with aPTH who improved by three months had less severe symptoms of mTBI, pain catastrophizing, and anxiety than those who did not improve. Furthermore, aPTH patients whose headaches did not improve had significantly greater baseline differences in brain structure vs. HC compared to those whose headaches did improve vs. HC. Conclusions: A model including clinical questionnaire data and measures of brain structure accurately predicted three-month headache improvement in patients with aPTH. Disclosure: Dr. Chong has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for HCOP. The institution of Dr. Chong has received research support from AMGEN. The institution of Dr. Chong has received research support from Department of Defense. The institution of Dr. Chong has received research support from NIH. An immediate family member of Dr. Chong has received intellectual property interests from a discovery or technology relating to health care. Prof. Li has nothing to disclose. Dr. Schwedt has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Allergan. Dr. Schwedt has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biohaven. Dr. Schwedt has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Eli Lilly. Dr. Schwedt has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Lundbeck. Dr. Schwedt has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Schwedt has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Ipsen. Dr. Schwedt has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Tonix Pharma. Dr. Schwedt has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Satsuma. Dr. Schwedt has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Biodelivery Science. Dr. Schwedt has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Abbvie. Dr. Schwedt has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Axsome. Dr. Schwedt has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Collegium. Dr. Schwedt has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Linpharma. Dr. Schwedt has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Theranica. Dr. Schwedt has stock in Aural Analytics. Dr. Schwedt has stock in Nocira. The institution of Dr. Schwedt has received research support from Amgen. The institution of Dr. Schwedt has received research support from National Institutes of Health. The institution of Dr. Schwedt has received research support from United States Department of Defense. The institution of Dr. Schwedt has received research support from Patient Centered Outcomes Research Institute. The institution of Dr. Schwedt has received research support from SPARK Neuro. The institution of Dr. Schwedt has received research support from Henry Jackson Foundation. Dr. Schwedt has received intellectual property interests from a discovery or technology relating to health care. Dr. Schwedt has received publishing royalties from a publication relating to health care. Visar Berisha has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Cytokinetics. Visar Berisha has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Boehringer Ingelheim. Visar Berisha has received personal compensation in the range of $10,000-$49,999 for serving as an officer or member of the Board of Directors for Aural Analytics. Visar Berisha has received stock or an ownership interest from Aural Analytics. The institution of Visar Berisha has received research support from Boheringer Ingelheim. Visar Berisha has received intellectual property interests from a discovery or technology relating to health care. Mr. Nikjou has nothing to disclose. Dr. Wu has nothing to disclose. Gina Dumkrieger has received personal compensation for serving as an employee of Mayo Clinic. The institution of Gina Dumkrieger has received research support from NIH. The institution of Gina Dumkrieger has received research support from DOD. The institution of Gina Dumkrieger has received research support from AMGEN. Katherine Ross has nothing to disclose. Ms. Mao has nothing to disclose.